A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients

4Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Tumor Associated Antigens (TAAs) are the privileged targets of almost all the cancer vaccines tested to date. Unfortunately all these vaccines failed to show a clinical efficacy. The main reason for this failure is the immune tolerance to TAAs that are self-proteins expressed by normal and cancer cells. Self-tolerance to TAAs is directed against their dominant rather than against their cryptic epitopes. The best way to overcome self-tolerance to TAAs would therefore be to target their cryptic epitopes. However, because of their low HLA-I affinity, cryptic peptides are nonimmunogenic and cannot be used to stimulate an antitumor immune response unless their immunogenicity has been previously enhanced. In this paper we describe a general approach to enhance immunogenicity of almost all the HLA-B*0702 restricted cryptic peptides derived from TAAs. It consists in substituting residues at position 1 or 9 of low HLA-B*0702 affinity cryptic peptides by an Alanine or a Leucine respectively. These substitutions increase affinity of peptides for HLA-B*0702. These optimized cryptic peptides are strongly immunogenic and very importantly CTL they stimulate recognize their native counterparts. TAAs derived optimized cryptic peptides can be considered as universal antitumor vaccine since they escape self-tolerance, are immunogenic and are not patient specific.

References Powered by Scopus

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

1414Citations
N/AReaders
Get full text

A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

1044Citations
N/AReaders
Get full text

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

929Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Peptide-based therapeutic cancer vaccine: Current trends in clinical application

124Citations
N/AReaders
Get full text

Vaccination with high-affinity epitopes impairs antitumor efficacy by increasing PD-1 expression on CD8<sup>+</sup> T cells

54Citations
N/AReaders
Get full text

Anti-cancer immunotherapies targeting telomerase

45Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Gallou, C., Rougeot, A., Graff-Dubois, S., Kosmatopoulos, K., & Menez-Jamet, J. (2016). A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients. Oncotarget, 7(37), 59417–59428. https://doi.org/10.18632/oncotarget.11086

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 7

64%

Researcher 4

36%

Readers' Discipline

Tooltip

Immunology and Microbiology 6

43%

Agricultural and Biological Sciences 5

36%

Pharmacology, Toxicology and Pharmaceut... 2

14%

Earth and Planetary Sciences 1

7%

Save time finding and organizing research with Mendeley

Sign up for free